DHA Peptide Regulations: What Dubai's New Circular Means for Clinics

What the circular covers

The circular brings peptide products used in licensed healthcare facilities under a single, defined framework. It sets out which product categories fall in scope and which facility types are affected, and establishes requirements across the areas an inspector will examine: procurement and storage, prescribing and administration, and record-keeping and reporting.

Clinics should read the full circular for the exact requirements and any transition or compliance deadline that applies to them — MedGrowth's authority rests on advising against the actual text, not a summary. The full circular is published on the DHA circulars portal under reference CIR-2026-00000107.

Why Dubai is regulating peptides now

Peptides have moved rapidly from specialist endocrinology into mainstream commercial wellness. Across global markets they are marketed for weight management, recovery, body composition and anti-ageing — often through channels with limited clinical oversight.

That growth has drawn regulatory attention internationally. Regulators in several major markets have moved to restrict which peptides may be compounded and how they may be supplied, generally citing product quality, immunogenicity risk and the thinness of safety data behind some compounds.

Dubai's position is consistent with that direction, but the framing matters. This is not a ban. It is a framework for handling peptide products inside licensed facilities — a materially different regulatory posture, and a more constructive one for operators who intend to do this properly.

What changes for clinics offering peptide therapies

Peptides become a clinical service, not a retail one. Anything sold as a wellness package, a membership add-on or a walk-in offering needs reviewing against the circular. The distinction between a medical service and a commercial wellness product is now a regulatory one, not a marketing one.

Documentation becomes the compliance exposure. Procurement, storage, prescribing and administration records are what an inspector examines. Clinics that have handled peptides informally will find this the hardest adjustment.

Marketing claims come under sharper scrutiny. Where a product is regulated as a controlled medical service, the claims made about it in advertising and on social media attract corresponding oversight.

Why regulation is good news for investors

There is a reflex in every clinical sector to read new regulation as a cost. In a market like Dubai's, the opposite is usually true.

An unregulated service cannot be insured, cannot be underwritten by a lender, and cannot be diligenced by an acquirer. Investors and healthcare groups do not buy revenue streams that sit outside a defined regulatory framework, because the risk cannot be priced. That is precisely why so much longevity revenue in the region has remained in small, owner-operated hands.

• Revenue becomes underwritable. A service delivered under a published standard can be valued, insured and financed.
• Compliance becomes a moat. Operators who invest in doing this properly gain a defensible position against those who do not.
• Consolidation becomes possible. Groups can acquire peptide-led clinics once there is a standard to diligence against.
• Insurer engagement becomes conceivable. Nothing enters an insurance framework before it enters a regulatory one.

Dubai has been explicit about its ambitions in longevity and preventive medicine. Regulation is not a brake on that. It is the infrastructure that lets institutional capital participate.

What clinic owners should do now

• Read CIR-2026-00000107 in full. Do not act on summaries, including this one.
• Audit your current peptide services against the circular — every product, every indication, every route of supply.
• Review procurement and storage. Establish where products are sourced and whether the chain of custody is documented.
• Check prescribing and administration records against what the circular requires.
• Review your marketing: website, social media, packages and price lists.
• Confirm your licensed scope covers what you offer. A recurring problem we see is clinics delivering services beyond their approved specialty scope — a risk that grows sharply once a service is explicitly regulated.

How MedGrowth helps

If you are acquiring or selling a facility with peptide-led revenue, this circular directly affects how that revenue should be valued.